Global pharmaceutical firm Pfizer is mulling an application to stay a lawsuit by Merck Sharp & Dohme seeking to invalidate a patent related to the blockbuster Prevnar 13 vaccine as it awaits the outcome of similar proceedings in the US.
Merck Sharp & Dohme has claimed ownership of a Pfizer patent related to the blockbuster Prevnar 13 vaccine, after a doctor who moved between the pharmaceutical companies and is listed as an author on the patent allegedly accessed confidential Merck documents before jumping ship to Pfizer.
The maker of the Yellow Pages and White Pages directories, Sensis, has won its IP case against a direct marketing company, with a judge ruling the rival’s Senses Direct mark was deceptively similar to its mark, both visually and aurally.
The court has ordered Australia’s biggest internet service providers to block seven websites from “ripping” audio files from music videos on YouTube, in what the judge described as “industrial scale copyright infringement”.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.
A showdown between global pharmaceutical giants over the world’s best selling vaccine began Monday in Federal Court, with Merck Sharp & Dohme claiming three patents for Prevnar 13 sold by Pfizer’s Wyeth are invalid and that its own vaccine offers greater protection against pneumococcal bacteria.